You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Recombinant fusion protein

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Latent Tuberculosis Infection Trial (Recombinant Mycobacterium tuberculosis fusion protein for injection, TB-PPD was injected)

Not yet recruiting
  • Latent Tuberculosis Infection
  • Recombinant Mycobacterium tuberculosis fusion protein for injection
  • TB-PPD was injected
  • (no location specified)
Feb 16, 2023

Latent Tuberculosis Infection Trial (Recombinant Mycobacterium Tuberculosis Fusion Protein, Purified Protein Derivative of

Not yet recruiting
  • Latent Tuberculosis Infection
  • Recombinant Mycobacterium Tuberculosis Fusion Protein
  • Purified Protein Derivative of Tuberculin
  • (no location specified)
Jun 8, 2023

Acute Gout Trial in Nanchang (rhTNFR-Fc, Triamcinolone Acetonide)

Not yet recruiting
  • Acute Gout
  • Nanchang, Jiangxi, China
    Department of Rheumatology and Clinical Immunology, Jiangxi Prov
Jun 28, 2023

Osteoporosis, Spinal Fusion Trial (RhBMP-2)

Not yet recruiting
  • Osteoporosis
  • Spinal Fusion
  • (no location specified)
Jun 20, 2023

Severe Hemophilia A Trial in China (FRSW117)

Not yet recruiting
  • Severe Hemophilia A
  • Beijing, China
  • +27 more
Nov 16, 2023

Health Volunteer Trial in Beijing (Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg, Recombinant human CTLA-4-FC

Recruiting
  • Health Volunteer
  • Recombinant human CTLA-4-FC fusion protein for injection 1mg/kg
  • +9 more
  • Beijing, China
    Peking University People's Hospital
Feb 15, 2022

COVID-19 Pandemic Trial in Zhuhai (Recombinant SARS-CoV-2 Fusion Protein Vaccine 10µg, Recombinant SARS-CoV-2 Fusion Protein

Active, not recruiting
  • COVID-19 Pandemic
  • Recombinant SARS-CoV-2 Fusion Protein Vaccine 10μg
  • +2 more
  • Zhuhai, Guangdong, China
    Zhuhai Peoples' Hospital Medical Group
Mar 12, 2022

Severe Hemophilia A Trial in China (ADVATE, FRSW117)

Completed
  • Severe Hemophilia A
  • Guangzhou, Guangzhou, China
  • +3 more
Jun 27, 2022

COVID-19 Pandemic Trial in Malaysia, Pakistan (Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01), Blank Preparation of

Active, not recruiting
  • COVID-19 Pandemic
  • Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)
  • Blank Preparation of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)
  • Kuching, Sarawak, Malaysia
  • +17 more
Aug 31, 2022

Hemophilia A Trial in China (ADVATE, FRSW107)

Recruiting
  • Hemophilia A
  • Beijing, Beijing, China
  • +5 more
Jun 27, 2022

COVID-19 Pandemic Trial in Zhuhai (Recombinant SARS-CoV-2 Fusion Protein Vaccine)

Active, not recruiting
  • COVID-19 Pandemic
  • Recombinant SARS-CoV-2 Fusion Protein Vaccine
  • Zhuhai, Guangdong, China
    The Fifth Peoples' Hospital of Zhuhai
Feb 15, 2022

COVID19 Trial in Guangzhou (Recombinant SARS-CoV-2 Fusion Protein Vaccine)

Completed
  • COVID19
  • Recombinant SARS-CoV-2 Fusion Protein Vaccine
  • Guangzhou, Guangdong, China
    Guangdong Provincial Center for Disease Control and Prevention
Feb 10, 2022

Healthy Trial in Shanghai (SI-F019)

Completed
  • Healthy
  • Shanghai, Shanghai, China
    Shanghai Public Health Clinical Center Ethics Committee Approval
Dec 11, 2022

COVID-19 Pandemic Trial in Indonesia, Philippines, Russian Federation (Recombinant SARS-CoV-2 fusion protein vaccine (V-01),

Active, not recruiting
  • COVID-19 Pandemic
  • Recombinant SARS-CoV-2 fusion protein vaccine (V-01)
  • Blank Preparation of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)
  • Padang, Indonesia
  • +24 more
Aug 31, 2022

Malignant Pleural Effusions Trial in Australia (SCB-313)

Completed
  • Malignant Pleural Effusions
  • Liverpool, New South Wales, Australia
  • +3 more
Feb 1, 2022

Advanced Malignant Solid Tumor Trial in Sacramento (CD24 Extracellular Domain-IgG1 Fc Domain Recombinant Fusion Protein CD24Fc,

Terminated
Has Results
  • Advanced Malignant Solid Neoplasm
  • CD24 Extracellular Domain-IgG1 Fc Domain Recombinant Fusion Protein CD24Fc
  • Placebo Administration
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Mar 8, 2022

COVID-19 Pandemic Trial in Zhuhai (Recombinant SARS-CoV-2 Fusion Protein Vaccine)

Active, not recruiting
  • COVID-19 Pandemic
  • Recombinant SARS-CoV-2 Fusion Protein Vaccine
  • Zhuhai, Guangdong, China
    Zhuhai Peoples' Hospital Medical Group
Nov 14, 2021

COVID-19, SARS-CoV-2 Acute Respiratory Disease Trial in Hanoi (COVID-19 Vaccine HIPRA, Cominarty (Pfizer-BioNtech))

Active, not recruiting
  • COVID-19
  • SARS-CoV-2 Acute Respiratory Disease
  • COVID-19 Vaccine HIPRA
  • Cominarty (Pfizer-BioNtech)
  • Hanoi, Vietnam
    National Institute of Hygiene and Epidemiology
Aug 2, 2022

Hematologic Malignancy Trial in Tianjin (IMM01)

Terminated
  • Hematologic Malignancy
  • Tianjin, Tianjin, China
    Chinese Academy of Medical Sciences and Peking Union Medical Col
May 5, 2023

COVID 19 Trial in Secaucus (HLX71, Placebo)

Completed
  • COVID 19
  • Secaucus, New Jersey
    Frontage Clinical Services, Inc.
Mar 20, 2022

Severe Hemophilia A Trial in China (FRSW107)

Not yet recruiting
  • Severe Hemophilia A
  • Baoding, China
  • +13 more
Nov 16, 2023

Chemo-induced Thrombocytopenia Trial in Shanghai (QL0911)

Completed
  • Chemotherapy-induced Thrombocytopenia
  • Shanghai, Shanghai, China
    Shanghai East Hospital
May 5, 2023

Infertility Trial in Chengdu, (GenSci094)

Recruiting
  • Infertility
  • Chengdu,, Sichuan, China
    Chengdu Xinhua Hospital, affiliated with Sichuan North Medical C
Oct 18, 2023

Tumor Malignant, Tumor, Experimental, Solid Tumor, Adult Trial in Taipei (JS014, Interleukin 21 and humanized anti-human serum

Active, not recruiting
  • Neoplasm Malignant
  • +3 more
  • JS014, Interleukin 21 and humanized anti-human serum albumin VHH antibody
  • Pembrolizumab - anti-PD-1 antibody
  • Taipei, Taiwan
    Wanfang Hospital -Taipei Medical University
Mar 16, 2022

Recurrent Bladder Carcinoma, Bladder Cancer Stage 0, Bladder Cancer Stage I Trial in Los Angeles (Pharmacokinetic Study,

Not yet recruiting
  • Recurrent Bladder Carcinoma
  • +2 more
  • Pharmacokinetic Study
  • Recombinant EphB4-HSA Fusion Protein
  • Los Angeles, California
    USC / Norris Comprehensive Cancer Center
Jan 31, 2023